On 13 December, NeuroVive Pharmaceutical AB (publ) held an Extraordinary General Meeting (EGM), whose resolutions are summarized in what follows. All resolutions were reached with the requisite majority.

Approval of the Board of Directors’ decision on a new share issue waiving shareholders’ preferential rights The Meeting approved the Board of Directors’ decision on the new issue of a maximum of 2,500,000 shares.